DK Business Network
American pharmaceutical company, Eli Lilly and Company has officially launched its weight-loss and diabetes medication, Mounjaro (tirzepatide), in India.
The company headquartered in Indianapolis, Indiana was founded in 1876 by Colonel Eli Lilly. The company is known for its innovation in developing and manufacturing a wide range of pharmaceutical products with a specialization in therapeutic areas.
This development by Eli Lilly marks a crucial step in addressing India’s growing public health challenges, particularly the rising rates of obesity and type 2 diabetes. Approved by Indian drug regulators, Mounjaro offers a novel solution, available in two dosages—2.5 mg priced at ₹3,500 and 5 mg at ₹4,375.
The drug helps regulate blood sugar levels, improve insulin sensitivity, control appetite, and slow down digestion, ultimately promoting significant weight loss. Clinical trials revealed that patients experienced an average weight loss of up to 21.8 kg over 72 weeks, especially when combined with a controlled diet and exercise.
Given India’s alarming statistics—over 100 million people living with diabetes and rapidly rising obesity rates—Mounjaro’s entry is seen as a timely intervention, providing healthcare professionals and patients with an effective new tool to manage these conditions.
Instagram: Click here
LinkedIn: Click here
For Collaboration and Business: dkbusinessnetwork@gmail.com